

ONCE-DAILY
NUPLAZID[®]
(pimavanserin) 34mg capsules

Start treatment for
Parkinson's disease (PD)-
related hallucinations and
delusions early—

EVERY MOVE MATTERS

Getting patients
started on NUPLAZID[®]



Actor Portrayals

Indication

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

- NUPLAZID has been studied in patients with PD-related hallucinations and/or delusions with or without dementia.¹
- The mean age of patients (N=199) enrolled in the Phase 3 study supporting NUPLAZID approval was 72 years, and patients had MMSE scores ≥ 21 .² At screening, 20% of patients (40/198) had a history of dementia per medical history, and 37% of patients (69/185) were taking anti-dementia medications at baseline.^{3,4}

Important Safety Information

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson's disease.

See additional Important Safety Information throughout. Please read the full [Prescribing Information](#), including **Boxed WARNING**, also available at [NUPLAZIDhcp.com](https://www.nuplazidhcp.com).

Dosing and administration for NUPLAZID®

Once-daily dose, no titration needed¹



34 mg taken orally, once daily

Taken with or without food

Taken whole or sprinkled

(Not actual size)*

*Actual size is 14.4 mm x 5.3 mm.

The NUPLAZID 34 mg capsule can be opened, and the entire contents sprinkled over a tablespoon (15 mL) of applesauce, yogurt, pudding, or a liquid nutritional supplement.¹ The drug/food mixture should be consumed immediately without chewing; do not store for future use.¹

Dosing considerations

- For patients taking strong CYP3A4 inhibitors, the recommended dose of NUPLAZID is 10 mg once daily¹
- Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID¹
- Avoid the use of NUPLAZID in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval^{1†}
- NUPLAZID does not require a dosage adjustment in elderly patients, in patients with mild to severe renal impairment or end-stage renal disease (ESRD),[‡] or in patients with hepatic impairment¹
- The steady-state plasma concentration of NUPLAZID was reached in ~12 days with continuous treatment, without titration⁵
 - Half-life ($t_{1/2}$) is 57 hours¹
- No dosage adjustment of carbidopa/levodopa is required when administered concomitantly with NUPLAZID¹

[†]In the 6-week placebo-controlled studies, NUPLAZID prolonged the QT interval (mean increase ~5-8 ms).¹

[‡]Increased exposure (C_{max} and AUC) to NUPLAZID occurred in patients with severe renal impairment ($CrCl < 30$ mL/min, Cockcroft-Gault) in a renal impairment study.¹ NUPLAZID should be used with caution in patients with severe renal impairment and ESRD.¹

ICD-10 diagnostic codes for Parkinson's disease (PD) psychosis

Your patient with PD-related hallucinations and delusions may need prior authorization to get coverage for NUPLAZID. View classification codes below. All coding decisions are ultimately the responsibility of each prescribing healthcare provider.

Coding combinations recognized for PD psychosis include any of the **G20 (PD) sub-codes (G20A.1, G20A.2, G20B.1, or G20B.2) plus one of the following ICD-10 codes⁶:**

- **F06.0 psychotic disorder with hallucinations due to known physiological condition**
- **F06.2 psychotic disorder with delusions due to known physiological condition**

99% of prior authorizations on Medicare Part D plans only require a basic confirmation of diagnosis and/or a specialty prescriber.⁵

⁵Formulary data current as of October 2023. Formulary status is subject to change. Please check with health plan to confirm.

Important Safety Information (con't)

- **Contraindication:** NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.

See additional Important Safety Information throughout. Please read the full [Prescribing Information](#), including **Boxed WARNING**, also available at NUPLAZIDhcp.com.

ONCE-DAILY
NUPLAZID®
(pimavanserin) 34mg capsules

Support for your practice and the families you care for

Prescribing NUPLAZID® (pimavanserin)

To prescribe NUPLAZID and enroll your patients in Acadia Connect®, complete the Treatment & Service Request Form, available at acadiacconnect.com/hcp-enrollment.

Prescribing through an EHR system

NUPLAZID can only be filled through the following in-network pharmacies:

- **Walgreens Specialty Pharmacy**
- **CVS Specialty Pharmacy**
- **Walmart Specialty Pharmacy**
- **Accredo**
- **CenterWell Specialty Pharmacy**

To get your patients the benefits of Acadia Connect, complete the **Treatment & Service Request Form** when e-prescribing.

Learn more about Acadia Connect



Acadia Connect helps ensure that it's easy for your patients to start and continue taking NUPLAZID with access, insurance, and prescription support.

Visit acadiacconnect.com/hcp for more information.

NUPLAZID is accessible and affordable

With comprehensive coverage and financial assistance support from Acadia Connect, your patient's NUPLAZID prescription may be more affordable than you think.



9 in 10 patients pay less than \$10 as final out-of-pocket costs for their prescription*



100% of Medicare Part D plans cover NUPLAZID†



\$0 co-pay for qualifying commercially covered patients‡

*Around 10% of patients may pay more than \$10 for their prescription. As reported by 4 specialty pharmacy organizations; Q1 and Q2 2023 data.

†Managed Markets Insight & Technology. Formulary Lookup website, <https://formularylookup.com>. Accessed July 22, 2024.

‡Acadia Connect patient [eligibility requirements and terms and conditions](#) apply.

Important Safety Information (con't)

- **Warnings and Precautions:** QT Interval Prolongation
 - NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3 antiarrhythmics, certain antipsychotics or antibiotics).
 - NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

See additional Important Safety Information throughout. Please read the full [Prescribing Information](#), including **Boxed WARNING**, also available at NUPLAZIDhcp.com.

For more information and resources to help your patients get started on treatment, visit [NUPLAZIDhcp.com/acadia-connect](https://www.nuplazidhcp.com/acadia-connect).

To request NUPLAZID[®] samples, visit [acadia.hcpordering.com](https://www.acadia.hcpordering.com).



Important Safety Information (con't)

- **Adverse Reactions:** The adverse reactions ($\geq 2\%$ for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs $<1\%$).
- **Drug Interactions:**
 - Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
 - Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

Dosage and Administration

Recommended dose: 34 mg capsule taken orally once daily, without titration, with or without food.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the accompanying full Prescribing Information, including **Boxed WARNING**, also available at [NUPLAZIDhcp.com](https://www.nuplazidhcp.com).

References: **1.** Acadia Pharmaceuticals Inc. NUPLAZID[®] [package insert]. San Diego, CA; 2023. **2.** Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. *Lancet*. 2014;383(9916):533-540. **3.** Acadia Pharmaceuticals Inc. Data on file. ACP-103-020 posthoc demographics. July 2020. **4.** Espay AJ, Guskey MT, Norton C, et al. Pimavanserin for Parkinson's disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications. *Mov Disord*. 2018;33(11):1769-1776. **5.** Acadia Pharmaceuticals Inc. NUPLAZID Advisory Committee Briefing Document. San Diego, CA: Sponsor Background Information for a Meeting of the Psychopharmacologic Drugs Advisory Committee; March 29, 2016. **6.** Centers for Medicare & Medicaid Services. *ICD-10-CM Tabular List of Diseases and Injuries*. Baltimore, MD: US Dept of Health and Human Services; 2020.